TY - JOUR
T1 - Effect of Low Doses of Methamphetamine on Rat Limbic-Related Neurotensin Systems
AU - Alburges, Mario E.
AU - Hoonakker, Amanda J.
AU - Cordova, Nathaniel M.
AU - Robson, Christina M.
AU - Mcfadden, Lisa M.
AU - Martin, Amber L.
AU - Hanson, Glen R.
N1 - Publisher Copyright:
© 2015 Wiley Periodicals, Inc.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Administration of methamphetamine (METH) alters limbic-related (LR) neurotensin (NT) systems. Thus, through a D1-receptor mechanism, noncontingent high doses (5-15 mg kg-1), and likely self-administration, of METH appears to reduce NT release causing its accumulation and an elevation of NT-like immunoreactivity (NTLI) in limbic-related NT pathways. For comparison, we tested the effect of low doses of METH, that are more like those used in therapy, on NTLI in the core and shell of the nucleus accumbens (NAc and NAs), prefrontal cortex (PFC), ventral tegmental area (VTA), the lateral habenula (Hb) and basolateral amygdala (Amyg). METH at the dose of 0.25 mg kg-1 in particular, but not 1.00 mg kg-1, decreased NTLI concentration in all of the LR structures studied, except for the prefrontal cortex; however, these effects were rapid and brief being observed at 5 h but not at 24 h after treatment. In all of the LR areas where NTLI levels were reduced after the low dose of METH, the effect was blocked by pretreatment with either a D1 or a D2 antagonist. Thus, opposite to high doses like those associated with abuse, the therapeutic-like low-dose METH treatment induced reduction in NT tissue levels likely reflected an increase in NT release and a short-term depletion of the levels of this neuropeptide in LR structures, manifesting features comparable to the response of basal ganglia NT systems to similar low doses of METH.
AB - Administration of methamphetamine (METH) alters limbic-related (LR) neurotensin (NT) systems. Thus, through a D1-receptor mechanism, noncontingent high doses (5-15 mg kg-1), and likely self-administration, of METH appears to reduce NT release causing its accumulation and an elevation of NT-like immunoreactivity (NTLI) in limbic-related NT pathways. For comparison, we tested the effect of low doses of METH, that are more like those used in therapy, on NTLI in the core and shell of the nucleus accumbens (NAc and NAs), prefrontal cortex (PFC), ventral tegmental area (VTA), the lateral habenula (Hb) and basolateral amygdala (Amyg). METH at the dose of 0.25 mg kg-1 in particular, but not 1.00 mg kg-1, decreased NTLI concentration in all of the LR structures studied, except for the prefrontal cortex; however, these effects were rapid and brief being observed at 5 h but not at 24 h after treatment. In all of the LR areas where NTLI levels were reduced after the low dose of METH, the effect was blocked by pretreatment with either a D1 or a D2 antagonist. Thus, opposite to high doses like those associated with abuse, the therapeutic-like low-dose METH treatment induced reduction in NT tissue levels likely reflected an increase in NT release and a short-term depletion of the levels of this neuropeptide in LR structures, manifesting features comparable to the response of basal ganglia NT systems to similar low doses of METH.
KW - Basal ganglia
KW - Dopamine antagonists
KW - Methamphetamine
KW - Neurotensin
KW - Stimulant
UR - http://www.scopus.com/inward/record.url?scp=84932146177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84932146177&partnerID=8YFLogxK
U2 - 10.1002/syn.21829
DO - 10.1002/syn.21829
M3 - Article
C2 - 25963809
AN - SCOPUS:84932146177
SN - 0887-4476
VL - 69
SP - 396
EP - 404
JO - Synapse
JF - Synapse
IS - 8
ER -